Join our LinkedIn PATENTSCOPE users Community Group
Feedback
Settings

Settings

Goto Application

1,732,493 results
Offices all Languages Stemming true Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 173,250
1.WO/2024/105092PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
WO - 23.05.2024
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
 Appl.No PCT/EP2023/081874 Applicant NEURIMMUNE AG Inventor MICHALON, Aubin
Transthyretin (TTR) is a soluble protein involved in thyroxin and retinol transport in the body. Under specific conditions the TTR protein adopts misfolded, misassembled and/or aggregated TTR conformations and becomes toxic, which can lead to transthyretin-mediated amyloidosis (ATTR). Provided herein are, inter alia, compositions (e.g., pharmaceutical compositions) and related articles of manufacture that contain an anti-TTR antibody or antigen fragment thereof. Additionally, provided herein are, inter alia, methods of treating or preventing ATTR using the pharmaceutical compositions described herein.
2.WO/2024/105197SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT
WO - 23.05.2024
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/EP2023/082123 Applicant VINCERX PHARMA GMBH Inventor LERCHEN, Hans-Georg
The present invention relates to novel pharmaceutical compounds comprising one or more binding molecules (e.g., target protein binders, T) capable of binding to target proteins expressed on tumor cells or on cells present in the tumor microenvironment, and which are linked via protease cleavable linkers to one or more payload molecules; the processes for preparation thereof; and to the use thereof for treating diseases and conditions, including hyperproliferative disorders such as cancer, in humans and other mammals.
3.WO/2024/105677MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF
WO - 23.05.2024
Int.Class A61K 31/198
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
 Appl.No PCT/IL2023/051191 Applicant TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED Inventor CIECHANOVER, Aaron
The present disclosure provides modulators of proteasome dynamics and/or function in a mammalian cell, compositions and uses thereof. The disclosed modulating compounds are characterized by affecting at least one of: mammalian target of rapamycin (mTOR) activation and/or lysosomal association, proteasome cellular localization, the activity and/or level/s and/or the post translational modification/s (PTM/s), and/or subcellular localization of at least one signaling molecule participating directly or indirectly in at least one pathway mediating said proteasome dynamics/function.
4.WO/2024/107012LACTIPLANTIBACILLUS PLANTARUM STRAIN, CULTURE MEDIUM DERIVED THEREFROM, AND ANTIALLERGIC USES THEREOF
WO - 23.05.2024
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
 Appl.No PCT/KR2023/018563 Applicant GI BIOME INC. Inventor JANG, Myung Ho
The present invention relates to a novel microorganism, a lysate and culture medium thereof, and an extract of the culture medium, and to antiallergic uses thereof. A novel strain, and a lysate or culture medium derived therefrom, an extract of the culture medium, or a mixture thereof according to one aspect can be usefully employed to prevent, alleviate, or treat allergic diseases.
5.WO/2024/107102USE OF CONDITIONED MEDIUM DERIVED FROM CULTIVATION OF MESENCHYMAL STEM CELLS OF THE UMBILICAL CORD FOR INDUCING, STIMULATING AND PROMOTING HAIR GROWTH AND REGENERATION
WO - 23.05.2024
Int.Class A61K 35/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
51Umbilical cord; Umbilical cord blood; Umbilical stem cells
 Appl.No PCT/SG2022/050834 Applicant CELLRESEARCH CORPORATION PTE. LTD. Inventor PHAN, Toan Thang
The present invention relates to a method of inducing, stimulating and/or promoting hair growth and/or hair regeneration, wherein the method comprises treating the hair of a subject with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. The present invention also relates to a method of alleviating and/or reducing hair loss and/or hair thinning, wherein the method comprises treating the hair a subject with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. The invention also relates to a method of producing a conditioned medium, the method comprising a) cultivating mesenchymal stem cells of the umbilical cord in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum); (b) removing the mesenchymal stem cells of the umbilical cord from the culture medium; wherein the conditioned medium is obtained by collecting the cell culture medium. The invention also relates to a conditioned medium obtained or obtainable by the producing method, a composition thereof and uses thereof.
6.WO/2024/103142PEPTIDES AND MAGNETIC PARTICLE-PEPTIDE CONJUGATES FOR PREVENTION OR TREATMENT OF GLAUCOMA
WO - 23.05.2024
Int.Class C07K 7/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
 Appl.No PCT/CA2022/051685 Applicant THE GOVERNORS OF THE UNIVERSITY OF ALBERTA Inventor UNSWORTH, Larry
Disclosed are peptides having specific affinity to exfoliation syndrome (XFS) deposits in a mammalian eye, and magnetic particle-peptide conjugates. Also disclosed are methods and uses of such magnetic particle-peptide conjugates to displace and remove XFS deposits, to prevent or treat XFS or exfoliation glaucoma (XFG).
7.WO/2024/103187FAP2-DERIVED ANTIBODIES AND VACCINES AGAINST FUSOBACTERIUM
WO - 23.05.2024
Int.Class C07K 14/195
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
 Appl.No PCT/CA2023/051551 Applicant PROVINCIAL HEALTH SERVICES AUTHORITY Inventor HOLT, Robert
A new composition of matter composed of engineered sequences for the expression of Fap2-derived polypeptides that provoke immunogenic responses against Fusobacterium spp. is provided. Antibodies and vaccines produced using such sequences and methods of use are also provided.
8.WO/2024/1042821H-PYRROLO[2,3-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE
WO - 23.05.2024
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No PCT/CN2023/131185 Applicant JS INNOMED HOLDINGS LTD. Inventor DENG, Zuyong
A compound as represented by formula (I) and/or a stereoisomer, tautomer or pharmaceutically acceptable salt or solvate of the compound of formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound of formula (I), and a use thereof as an Myt1 kinase inhibitor in medicine.
9.WO/2024/104417METHOD OF PREPARING AMISULPRIDE TABLETS
WO - 23.05.2024
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
 Appl.No PCT/CN2023/131981 Applicant HQ PHARMA (SHANDONG) CO., LTD. Inventor SONG, Yijun
A method of preparing amisulpride tablets, belonging to the technical field of medicine preparation. The method mainly comprises the following steps: coating amisulpride with a coating material, and then selecting a hydrophilic lubricant and mixing same with the coated particles. The invention provides a brand-new solution for the problem of punch-sticking caused by properties inherent to amisulpride. By coating amisulpride with a polymer coating material and then selecting a lubricant having good hydrophilicity and mixing same with the coated particles, the method not only solves the problem of punch-sticking that often occurs with amisulpride, but also yields amisulpride tablets that have a high degree of hardness and a favorable dissolution rate.
10.WO/2024/104462GPR17 MODULATORS AND USES THEREOF
WO - 23.05.2024
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No PCT/CN2023/132327 Applicant MYROBALAN THERAPEUTICS NANJING CO. LTD Inventor HAN, Xiao
Disclosed herein are compounds capable of modulating GPR17 and pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., neurodegenerative diseases or demyelinating diseases, using such pharmaceutical compositions.
# -